| 產(chǎn)品編號 | bs-21778R |
| 英文名稱 | Rabbit Anti-PD-L1 antibody |
| 中文名稱 | 程序性死亡配體1（CD274）抗體 |
| 別 名 | Programmed cell death 1 ligand 1; CD274; B7 H; B7 H1; B7 homolog 1; B7-H1; B7H; B7H1; CD 274; CD274 antigen; CD274 molecule; MGC142294; MGC142296; OTTHUMP00000021029; PD L1; PD1L1_HUMAN; PDCD1 ligand 1; PDCD1L1; PDCD1LG1; PDL 1; PDL1; Programmed death ligand 1; RGD1566211. |
 |
Specific References (1) | bs-21778R has been referenced in 1 publications.
[IF=2.303] Suihui Li. et al. Hsa_circ_0048674 facilitates hepatocellular carcinoma progression and natural killer cell exhaustion depending on the regulation of miR-223-3p/PDL1. Histol Histopathol. 2022 Feb 21;18440 WB ; Human,Mouse.
|
| 研究領(lǐng)域 | 腫瘤 免疫學(xué) 細胞類型標志物 |
| 抗體來源 | Rabbit |
| 克隆類型 | Polyclonal |
| 交叉反應(yīng) | Human,Mouse,Rat (predicted: Pig,Sheep,Cow,Horse) |
| 產(chǎn)品應(yīng)用 | WB=1:500-2000,ELISA=1:5000-10000
not yet tested in other applications. optimal dilutions/concentrations should be determined by the end user. |
| 理論分子量 | 32kDa |
| 細胞定位 | 細胞膜 |
| 性 狀 | Liquid |
| 濃 度 | 1mg/ml |
| 免 疫 原 | KLH conjugated synthetic peptide derived from human B7-H1/PDL1/CD274: 64-160/290 <Extracellular> |
| 亞 型 | IgG |
| 純化方法 | affinity purified by Protein A |
| 緩 沖 液 | 0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
| 保存條件 | Shipped at 4℃. Store at -20℃ for one year. Avoid repeated freeze/thaw cycles. |
| 注意事項 | This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications. |
| PubMed | PubMed |
| 產(chǎn)品介紹 |
This gene encodes an immune inhibitory receptor ligand that is expressed by hematopoietic and non-hematopoietic cells, such as T cells and B cells and various types of tumor cells. The encoded protein is a type I transmembrane protein that has immunoglobulin V-like and C-like domains. Interaction of this ligand with its receptor inhibits T-cell activation and cytokine production. During infection or inflammation of normal tissue, this interaction is important for preventing autoimmunity by maintaining homeostasis of the immune response. In tumor microenvironments, this interaction provides an immune escape for tumor cells through cytotoxic T-cell inactivation. Expression of this gene in tumor cells is considered to be prognostic in many types of human malignancies, including colon cancer and renal cell carcinoma. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Sep 2015] Function: Involved in the costimulatory signal, essential for T-cell proliferation and production of IL10 and IFNG, in an IL2-dependent and a PDCD1-independent manner. Interaction with PDCD1 inhibits T-cell proliferation and cytokine production. Subunit: Interacts with PDCD1. Subcellular Location: Isoform 1: Cell membrane; Single-pass type I membrane protein. Isoform 2: Endomembrane system; Single-pass type I membrane protein. Tissue Specificity: Highly expressed in the heart, skeletal muscle, placenta and lung. Weakly expressed in the thymus, spleen, kidney and liver. Expressed on activated T- and B-cells, dendritic cells, keratinocytes and monocytes. Similarity: Belongs to the immunoglobulin superfamily. BTN/MOG family. Contains 1 Ig-like C2-type (immunoglobulin-like) domain. Contains 1 Ig-like V-type (immunoglobulin-like) domain. SWISS: Q9NZQ7 Gene ID: 29126 Database links: Entrez Gene: 29126 Human Entrez Gene: 60533 Mouse Omim: 605402 Human SwissProt: Q9NZQ7 Human SwissProt: Q9EP73 Mouse Unigene: 521989 Human Unigene: 245363 Mouse |
| 產(chǎn)品圖片 |
Sample:
Lovo(Human) Cell Lysate at 30 ug
Heart(Mouse) Lysate at 40 ug
Kidney(Mouse) Lysate at 40 ug
Muscle(Mouse) Lysate at 40 ug
Heart(Rat) Lysate at 40 ug
Muscle(Rat) Lysate at 40 ug
Primary: Anti-PD-L1 (bs-21778R) at 1/500 dilution
Secondary: IRDye800CW Goat Anti-Rabbit IgG at 1/20000 dilution
Predicted band size: 50 kD
Observed band size: 53 kD
|
| 1、抗體溶解方法 | |
| 2、抗體修復(fù)方式 | |
| 3、常用試劑的配制 | |
| 4、免疫組化操作步驟 | |
| 5、免疫組化問題解答 | |
| 6、Western Blotting 操作步驟 | |
| 7、Western Blotting 問題解答 | |
| 8、關(guān)于肽鏈的設(shè)計 | |
| 9、多肽的溶解與保存 | |
| 10、酶標抗體效價測定程序 | |
